Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

被引：1
|
作者：
Di, Mengyang [1 ,2 ]
Long, Jessica B. [1 ]
Kothari, Shalin K. [3 ]
Sethi, Tarsheen [3 ]
Zeidan, Amer M. [1 ,3 ]
Podoltsev, Nikolai A. [1 ,3 ]
Shallis, Rory Michael [1 ,3 ]
Wang, Rong [1 ,4 ]
Stempel, Jessica M. [2 ]
Ma, Xiaomei [1 ,4 ]
Huntington, Scott F. [1 ,3 ]
机构：
[1] Yale Univ, Sch Med, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA
[2] Yale Univ, Dept Internal Med, Hematol Oncol, Sch Med, New Haven, CT USA
[3] Yale Univ, Dept Internal Med, Sect Hematol, Sch Med, New Haven, CT USA
[4] Yale Univ, Dept Chron Dis Epidemiol, Sch Publ Hlth, New Haven, CT USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-164959
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10904 / 10906
页数：3
相关论文
共 50 条
  • [31] Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.
    Karmali, Reem
    Switchenko, Jeffrey M.
    Goyal, Subir
    Bachanova, Veronika
    Gerson, James
    Barta, Stefan K.
    Danilov, Alexey Valeryevich
    Grover, Natalie Sophia
    Epperla, Narendranath
    Burkart, Madelyn
    Sawalha, Yazeed
    Ghosh, Nilanjan
    Bond, David Alan
    Maddocks, Kami J.
    Badar, Talha
    Fenske, Timothy
    Guo, Jin
    Malecek, Mary-Kate
    Martin, Peter
    Cohen, Jonathon Brett
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Michael
    Hoa Pham
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir
    BLOOD, 2023, 142
  • [33] Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting
    Davids, Matthew S.
    Ambrose, Jacob
    De Nigris, Enrico
    Prescott, Jennifer
    Leng, Siyang
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Zettler, Christina M.
    Fernandes, Laura L.
    Wang, Ching-Kun
    Shadman, Mazyar
    BLOOD, 2023, 142
  • [34] Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in US routine clinical practice.
    Martin, Peter
    Kumar, Michael Wang Anita
    Qi, Keqin
    Daly, Katherine
    Parisi, Lori
    Zhu, Angeline
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Role of Bruton Tyrosine Kinase Inhibitors (BTKi) in Relapsed Refractory (r/r) Hairy Cell Leukaemia Patients: A Single-Centre Real-World Data Set from the Royal Marsden Hospital
    Sillito, Francesca Emily
    Pickard, Lucy
    Miriam, Ravindi
    Shah, Paras
    Iyengar, Sunil
    El-Sharkawi, Dima
    BLOOD, 2024, 144 : 6311 - 6312
  • [36] Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
    Nuno Cerveira
    Bruno Loureiro
    Susana Bizarro
    Cecília Correia
    Lurdes Torres
    Susana Lisboa
    Joana Vieira
    Rui Santos
    Dulcineia Pereira
    Cláudia Moreira
    Sérgio Chacim
    Nélson Domingues
    Ana Espírito-Santo
    Isabel Oliveira
    Ilídia Moreira
    Luísa Viterbo
    Ângelo Martins
    Manuel R. Teixeira
    José M. Mariz
    BMC Cancer, 18
  • [37] Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
    Cerveira, Nuno
    Loureiro, Bruno
    Bizarro, Susana
    Correia, Cecilia
    Torres, Lurdes
    Lisboa, Susana
    Vieira, Joana
    Santos, Rui
    Pereira, Dulcineia
    Moreira, Claudia
    Chacim, Sergio
    Domingues, Nelson
    Espirito-Santo, Ana
    Oliveira, Isabel
    Moreira, Ilidia
    Viterbo, Luisa
    Martins, Angelo
    Teixeira, Manuel R.
    Mariz, Jose M.
    BMC CANCER, 2018, 18
  • [38] Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma in Btki Era: A Multi-Center Real-World Study in China
    Cong, Mengya
    Jia, Junlei
    Liang, Zhanli
    Cao, Luming
    Zhang, Huilai
    Li, Wenyu
    Bai, Ou
    Huang, Haiwen
    BLOOD, 2024, 144 : 7813 - 7814
  • [39] Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nonomura, Norio
    Uemura, Motohide
    ANTICANCER RESEARCH, 2021, 41 (11) : 5811 - 5816
  • [40] Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
    Yang, Ping
    Cai, Qing-qing
    Zhang, Wei
    Liu, Shuo-zi
    Liu, Hui
    Sun, Xiu-hua
    Dong, Yu-jun
    Xiao, Xiu-bin
    Wang, Jing-wen
    Li, Zhen-ling
    Huang, Wen-rong
    Li, Li-hong
    Bao, Hui-zheng
    Yang, Wei
    Wang, Ya-lan
    Wang, Shu-ye
    He, Juan
    Li, Xiao-ling
    Liu, Ai-chun
    Jing, Hong-mei
    CANCER MEDICINE, 2023, 12 (12): : 13204 - 13216
12345